Minerva Neurosciences Inc (NERV) Upgraded by ValuEngine to “Hold”
Minerva Neurosciences Inc (NASDAQ:NERV) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
Several other brokerages also recently commented on NERV. Zacks Investment Research raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Friday, March 17th. Jefferies Group LLC started coverage on Minerva Neurosciences in a report on Monday, March 6th. They issued a “buy” rating and a $17.00 target price on the stock.
Shares of Minerva Neurosciences (NASDAQ:NERV) traded down 5.556% during mid-day trading on Tuesday, reaching $7.225. The company’s stock had a trading volume of 92,750 shares. Minerva Neurosciences has a 12 month low of $3.45 and a 12 month high of $15.84. The company has a 50 day moving average of $7.34 and a 200-day moving average of $10.02. The firm’s market capitalization is $265.19 million.
Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30). Equities research analysts forecast that Minerva Neurosciences will post ($1.50) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Minerva Neurosciences Inc (NERV) Upgraded by ValuEngine to “Hold”” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/23/minerva-neurosciences-inc-nerv-upgraded-by-valuengine-to-hold.html.
In other Minerva Neurosciences news, Director Marc D. Beer bought 50,000 shares of the stock in a transaction dated Monday, March 20th. The shares were bought at an average cost of $8.12 per share, with a total value of $406,000.00. Following the completion of the acquisition, the director now owns 25,000 shares of the company’s stock, valued at $203,000. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 28.10% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in NERV. ClariVest Asset Management LLC boosted its position in shares of Minerva Neurosciences by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 300 shares in the last quarter. TD Asset Management Inc. boosted its position in shares of Minerva Neurosciences by 1.3% in the first quarter. TD Asset Management Inc. now owns 27,100 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 357 shares in the last quarter. Handelsbanken Fonder AB boosted its position in shares of Minerva Neurosciences by 35.7% in the first quarter. Handelsbanken Fonder AB now owns 95,000 shares of the biopharmaceutical company’s stock valued at $770,000 after buying an additional 25,000 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Minerva Neurosciences by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 1,286 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Minerva Neurosciences during the fourth quarter valued at approximately $839,000. 69.81% of the stock is currently owned by institutional investors.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.